Project Grant R01CA298151
Award Date 8/1/26
Completion Date 7/31/31
Dollars Obligated $700K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Madison, WI 53715, USA
Similar Awards
- The National Cancer Institute awarded the University of Chicago $547,740 on July 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to define the molecular mechanisms by which the MLL1 histone modification complex and the long noncoding RNA HOTTIP interact in acute myeloid leukemia pathogenesis. The research examines whether non-specific RNA binding to the WDR5 subunit of the MLL1 complex inhibits the complex's histone methyltransferase activity and whether the RBBP5...
- The National Cancer Institute awarded the Regents of the University of Michigan $622,070 on September 3, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393, Project Grant R01CA315895) to investigate the oncogenic functions of ENL and AF9 proteins in acute myeloid and lymphoid leukemias. The research characterizes biochemical and functional differences between ENL and AF9, which are common translocation partners of the MLL (KMT2A) epigenetic regulator in leukemia...
- The National Cancer Institute, part of the National Institutes of Health, awarded $508,651 to the University of Wisconsin–Madison on June 2, 2026, under the Cancer Biology Research program (CFDA 93.396) to define and exploit therapeutically the role of neuropeptide receptor PAC1 in tumor-infiltrating pericytes during melanoma progression. The research investigates how PACAP-expressing neurons within the melanoma microenvironment interact with PAC1-expressing pericytes to drive disease...
- The National Cancer Institute awarded Northwestern University $593,307 on September 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate molecular mechanisms underlying nucleophosmin 1 (NPM1)-driven acute myeloid leukemia leukemogenesis. The funded research examines how NPM1 cytoplasmic mutations (NPM1c), which occur in approximately 30 percent of adult de novo AML cases, cooperate with clonal hematopoiesis mutations in DNMT3A, TET2, or IDH1/2 to promote leukemic...
- The National Cancer Institute awarded The Washington University Office of Sponsored Research Services $643,286 on August 1, 2026, to investigate DNA methylation epimutations in acute myeloid leukemia under the Cancer Biology Research program (CFDA 93.396). The research investigates allele-specific DNA methylation epimutations as clonal events that arise in normal cells and may be selected for during leukemogenesis. The project uses primary human acute myeloid leukemia samples, normal...
- The National Cancer Institute (a component of the Department of Health and Human Services National Institutes of Health) awarded Northwestern University $1,431,654 on September 23, 2025, under the Cancer Biology Research program (CFDA 93.396) to investigate how leukemia stem cell persistence during tyrosine kinase inhibitor treatment in chronic myeloid leukemia is influenced by interaction with CD8+ T cells. The research will employ single-cell RNA sequencing and murine transplant models to...
- The National Cancer Institute awarded the Regents of the University of Michigan $646,881 on April 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop small-molecule inhibitors of ASH1L, a histone methyltransferase, as a therapeutic strategy for acute leukemia. The funded research targets acute myeloid leukemia (AML), which carries a five-year survival rate of approximately 27% with current treatments. The work focuses on blocking expression of HOX genes—particularly...
- The National Cancer Institute awarded the Regents of the University of Minnesota $573,262 on April 17, 2026, under the Cancer Biology Research program (CFDA 93.396) to develop autologous humanized leukemia models for immunotherapy testing. The recipient will generate patient-derived xenograft models using paired leukemia and immune cells from the same pre-B acute lymphoblastic leukemia patient, addressing a gap in preclinical testing where current models either lack functional immune systems...
- The National Cancer Institute awarded the University of Alabama at Birmingham $576,965 on August 15, 2026, under the Cancer Biology Research program (CFDA 93.396) to decipher and target epigenetic accessory proteins in acute myeloid leukemia. The project investigates epigenetic complexes composed of catalytic core enzymes and accessory proteins that regulate gene expression and contribute to cancer development. Most existing therapies target catalytic cores, often causing widespread chromatin...
- The National Cancer Institute, a division of the Department of Health and Human Services, awarded the University of Illinois $422,649 as a Project Grant (R21CA303745) on June 1, 2026, under the Cancer Biology Research program (CFDA 93.396). The award funds research into racial disparities in acute myeloid leukemia (AML) treatment outcomes. The study examines whether NPM1 mutant status determines FOXM1 cytoplasmic localization and inactivation in primary bone marrow samples from Black AML...